

## Corporate Profile



## Fresenius Medical Care

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2 million individuals worldwide. Through its network of 2,838 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 225,909 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

## Growth Strategy

## With GOAL 13...

...new targets of the growth strategy were adopted in September 2010. Thereby we follow up the previous strategy, continuing to pursue the strategic four paths consistently in a financially responsible way to consolidate our position as world market leader in dialysis:

- Organic growth in dialysis services by innovative treatment techniques and the opening of new clinics
- Acquisitions of existing clinics to ensure optimized international presence
- Horizontal expansion in the sector of Renal Drugs as well as
- A boosted activity in home therapies

## Key Figures - Summary Second Quarter 2011

Net revenue	\$ 3,194 million	+ 8%
Operating income (EBIT)	\$ 510 million	+ 9%
Net income attributable to Fresenius Medical Care AG & Co. KGaA	\$ 261 million	+ 5%
Earnings per share	\$ 0.86	+ 4%
Total assets <sup>1</sup>	\$ 19,053 million	
Operating cash flow <sup>2</sup>	\$ 487 million	
Employees <sup>1</sup>	77,081	+ 5%
Patients <sup>1</sup>	225,909	+ 12%
Clinics <sup>1</sup>	2,838	+ 10%
Treatments <sup>2</sup>	16.56 million	+ 9%

<sup>1</sup> as of June 30, 2011

<sup>2</sup> in the first half of 2011

Revenue Q2 2011 per region  
(\$ 3,194 m)

## Goals for 2011

Net revenue	> \$ 13.0 billion
Net income	\$ 1.070 - 1.090 billion
Leverage ratio (Debt/EBITDA)	< 3.0
Capital expenditures	~ 5% of revenue
Acquisitions	~ \$ 1.9 billion

## Management Board

- Dr. Ben J. Lipps (Chairman)
- Rice Powell (Vice Chairman)
- Michael Brosnan
- Roberto Fusté
- Dr. Emanuele Gatti
- Dr. Rainer Runte
- Kent Wanzek

## Supervisory Board

- Dr. Gerd Krick (Chairman)
- Dr. Dieter Schenk (Vice Chairman)
- Dr. Walter L. Weisman
- Rolf A. Classon
- William P. Johnston
- Prof. Dr. Bernd Fahrholz

## Share Profile – Key Data

### Ticker Symbols

Frankfurt Stock Exchange	FME
New York Stock Exchange (NYSE)	FMS
Reuters: XETRA / Frankfurt Stock Exchange	FMEG.DE / FMEG.F
Bloomberg	FME GY

### Ordinary shares

FME
FMS
FMEG.DE / FMEG.F
FME GY

### Preference shares

FME3
FMS/P
FMEG_p.DE / FMEG_p.F
FME3 GY

### Security Identification Numbers

WKN	578 580
ISIN	DE 0005785802
CUSIP No. (NYSE)	358029106

578 580
DE 0005785836
358029205

### Preference shares

578 583
DE 0005785836
358029205


## Financing Instruments and Maturity Profile

	Year issued	Amount in million	Coupon %	Maturity
Credit Agreement Term Loan A	2006	\$ 1,850 <sup>1</sup>		March 31, 2013
Credit Agreement Term Loan B	2006	\$ 1,750 <sup>1</sup>		March 31, 2013
Senior Notes 2010 - 2016	2010	€ 250	5.500%	July 15, 2016
Senior Notes 2007 - 2017	2007	\$ 500	6.875%	July 15, 2017
Senior Notes 2011 - 2021	2011	\$ 650	5.750%	February 15, 2021
Senior Notes 2011 - 2021	2011	€ 300	5.250%	February 15, 2021
Notes (Schuldscheindarlehen)	2009	€ 155		October 27, 2012
Notes (Schuldscheindarlehen)	2009	€ 45		October 27, 2014

<sup>1</sup> at the beginning before amortisation and extension

## Share Price Development last 12 months

in €



## Capital Structure

### Overview

Ordinary Shares	~ 36%	~ 64%	299.07 m shares
Preference Shares	100%		3.96 m shares
Fresenius SE & Co. KGaA		Free Float	

## Financial Calendar

### Event

### Report on Second Quarter 2011

Quarterly Financial Report: August 31, 2011

### Report on Third Quarter 2011

Earnings Release & Conference Call: Nov. 2, 2011  
Quarterly Financial Report: Nov. 30, 2011

### Report on Fiscal Year 2011:

February 21, 2011

### Report on First Quarter 2012:

May 3, 2012

### Annual General Meeting 2012:

May 10, 2012

### Report on Second Quarter 2012:

August 1, 2012

### Report on Third Quarter 2012:

October 31, 2012

## Contacts

Fresenius Medical Care AG & Co. KGaA  
Investor Relations & Corporate Communications  
Else-Kröner-Straße 1 61352 Bad Homburg

**Oliver Maier** P: +49(0)6172-609-2525  
Senior Vice President, F: +49(0)6172-609-2301  
Head of IR & CC

**Gerrit Jost** P: +49(0)6172-609-5216  
Director

*North America*  
**Terry L. Morris** P: +1-800-948-2538  
Vice President F: +1-615-345-5605